Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment of optic nerve disease and for chronic traumatic encephalopathy (CTE). In 2017, Noveome announced positive data from a preclinical study of … [Read more...] about Noveome Biotherapeutics raises $15 million for development of ST266
Business
Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for the treatment of lung cancer. The company cites published studies showing lower risk of lung cancer with aspirin use and the potential of aspirin to inhibit … [Read more...] about Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Pulmatrix raises $16.6 million in public offering
Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The company had previously said that it expected to raise $14.4 … [Read more...] about Pulmatrix raises $16.6 million in public offering
Par Pharmaceutical launches authorized generic of Proventil HFA in US
Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par Pharmaceutical has already started shipping the inhaler, the company said. 3M Drug Delivery Systems manufactures Proventil … [Read more...] about Par Pharmaceutical launches authorized generic of Proventil HFA in US
Opiant Pharmaceuticals gets additional funding for intranasal nalmefene
Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company previously received $2.6 million from the grant, which is worth up to a total … [Read more...] about Opiant Pharmaceuticals gets additional funding for intranasal nalmefene
Cip Tec and Pulmatrix agree on terms for acquisition of rights to Pulmazole itraconazole DPI for ABPA
Pulmatrix announced that it has signed an agreement with Cipla subsidiary Cipla Technologies (Cip Tec) that "lays the groundwork" for Cip Tec to acquire the rights to Pulmazole (PUR1900) inhaled dry powder itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. A definitive deal is expected in the 2nd quarter of 2019, … [Read more...] about Cip Tec and Pulmatrix agree on terms for acquisition of rights to Pulmazole itraconazole DPI for ABPA
MannKind gets first milestone payment from United Therapeutics for treprostinil DPI development
MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial hypertension. The company did not specify what milestone had been achieved. United Therapeutics and MannKind announced the … [Read more...] about MannKind gets first milestone payment from United Therapeutics for treprostinil DPI development
Third Pole Therapeutics to collaborate with Actelion on inhaled nitric oxide development
Third Pole Therapeutics, which is developing an inhaled nitric oxide (iNO) generator, has announced a strategic collaboration agreement with Actelion Pharmaceuticals. Details of the agreement were not specified. Third Pole's iNO platform is designed for more convenient delivery than the compressed gas cylinders currently in use. The Third Pole device is primarily … [Read more...] about Third Pole Therapeutics to collaborate with Actelion on inhaled nitric oxide development
Janssen partners with Monash University on development of inhaled oxytocin
Johnson & Johnson subsidiary Janssen Pharmaceutica has announced that it signed a sponsored research agreement with Monash University's Monash Institute of Pharmaceutical Sciences (MIPS) for development of an inhaled dry powder oxytocin for the prevention and treatment of postpartum hemorrhage. No financial details were included in the announcement. According … [Read more...] about Janssen partners with Monash University on development of inhaled oxytocin
Ultibro Breezhaler and Seebri Breezhaler launched in China
According to Sosei, Novartis has launched the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in China for the treatment of COPD. Huizheng Technology acquired the Chinese licenses for the inhalers from Novartis and has filed applications to add both DPIs to the national health insurance drug list, Sosei … [Read more...] about Ultibro Breezhaler and Seebri Breezhaler launched in China